August 2025 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements, among other things, relate to the Company's growth drivers and expected levels of our organic growth; the impact of our in ...

Financial Performance - Lifecore Biomedical recorded $31.1 million in revenue for the three months ended September 30, 2025, representing a 26% increase from $24.7 million in the comparable prior period[11] - The company achieved a gross profit of $7.8 million, up from $5.4 million in the prior year, driven by a $4.3 million increase in HA manufacturing gross profit[13] - Total revenues for the three months ended September 30, 2025, were $31,109,000, a 25.9% increase from $24,705,000 for the same period in 2024[35] - Gross profit for the same period was $7,791,000, compared to $5,387,000 in the prior year, reflecting a 44.6% increase[35] - Adjusted EBITDA for the three months ended September 30, 2025, was $3,050,000, a significant improvement from a loss of $1,793,000 in the same period of 2024[38] - Lifecore's Adjusted EBITDA for the period was $3.1 million, an increase of $4.9 million compared to a negative $1.8 million in the prior year[16] - The net loss for the three months ended September 30, 2025, was $9,991,000, an improvement from a net loss of $16,230,000 in the same period of 2024[35] - Estimated net loss for the seven-month transition period from May 26, 2025, to December 31, 2025, is projected to be between $18,400,000 and $16,400,000[40] Cost Management - Selling, general and administrative expenses decreased by $5.9 million to $8.9 million compared to $14.8 million in the prior period, reflecting cost management efforts[14] - The company plans to launch a new ERP system in Q1 2026 to enhance inventory control and financial management, contributing to cost reduction[12] Operational Efficiency - Lifecore has improved workforce productivity in manufacturing by over 20% over the past year, reflecting its commitment to operational efficiency[12] - The company is focused on maximizing existing customer business and advancing late-stage development programs towards commercialization[3] Future Outlook - The company expects revenue for the transition period from May 26 to December 31, 2025, to be approximately $74 to $76 million, with a net loss projected between $18.4 million and $16.4 million[19] - Lifecore aims for a revenue CAGR of 12%+ and adjusted EBITDA margins exceeding 25% over the mid-term[3] - The company aims to achieve a revenue CAGR of over 12% and increase Adjusted EBITDA margins to more than 25% in the mid-term[30] Balance Sheet - The current assets as of September 30, 2025, totaled $83,928,000, slightly down from $85,677,000 as of May 25, 2025[33] - The total liabilities as of September 30, 2025, were $198,418,000, compared to $191,909,000 as of May 25, 2025[33] - The company reported a weighted average of 37,402,912 shares outstanding for the three months ended September 30, 2025[35] Corporate Changes - The company plans to transition its fiscal year end to align with the calendar year, effective for the December 31, 2025, period[39] - Lifecore signed two new programs during the quarter, including one late-stage and one early-stage program, expanding its service capabilities beyond ophthalmic therapeutics[6]

Core Insights - Lifecore Biomedical reported $31.1 million in revenue for the three months ended September 30, 2025, marking a 26% increase from the same period in 2024 [11][4] - The company has signed multiple new programs with customers, indicating growth in its project pipeline [8][3] - Lifecore is focused on improving efficiency and productivity across its operations, achieving over a 20% increase in workforce productivity in manufacturing over the past year [7][4] Financial Performance - Revenue increased by $6.4 million compared to the prior year, driven by a $4.8 million rise in hyaluronic acid (HA) manufacturing revenues and a $1.6 million increase in CDMO revenues [11][12] - Gross profit for the period was $7.8 million, up from $5.4 million in the prior year, attributed to increased sales volume and manufacturing absorption [12][11] - Selling, general, and administrative expenses decreased significantly to $8.9 million from $14.8 million, reflecting cost management efforts [13][11] Strategic Initiatives - Lifecore's growth strategy includes maximizing existing customer business, advancing late-stage development programs, and acquiring new impactful business [3][4] - The company is preparing for a significant increase in customer demand expected in 2027 by qualifying new HA specifications for the Asian market [5][4] - Lifecore plans to implement a new enterprise resource planning (ERP) system in Q1 2026 to enhance inventory control and financial management [9][4] Future Guidance - For the transition period from May 26 to December 31, 2025, Lifecore expects revenue between $74 million and $76 million, with a net loss projected between $18.4 million and $16.4 million [19][10] - Adjusted EBITDA for the transition period is anticipated to be in the range of $12 million to $14 million, reflecting the company's ongoing efforts to grow and diversify its revenue streams [19][10]

Core Viewpoint - Lifecore Biomedical, Inc. will report its financial results for the three months ended September 30, 2025, on November 6, 2025, after market close, followed by a webcast discussion with senior management [1]. Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [3]. - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across various therapeutic categories [3].

Core Insights - Laughing Water Capital reported a decline of approximately -1% in Q3 2025, with year-to-date returns at approximately -2.7%, underperforming compared to the SP500TR and R2000 which returned 12.4% and 8.1% respectively in the quarter [1] Company Analysis: Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Lifecore Biomedical, Inc. is identified as an integrated contract development and manufacturing organization, with a one-month return of -1.53% and a 52-week gain of 19.16% [2] - As of October 29, 2025, Lifecore's stock closed at $7.06 per share, with a market capitalization of $264.512 million [2] - The company has excess capacity in a market where demand exceeds supply, which is expected to lead to significant operating leverage due to high fixed costs and low variable costs [3] - Lifecore announced multiple new customer wins in Q3 2025, including partnerships with a GLP-1 and a large international pharmaceutical company, indicating a positive trend in securing additional business [3] - Regulatory changes, such as the FDA prioritizing domestically manufactured drugs and potential tariffs on foreign manufacturers, are expected to benefit Lifecore's business model [3] - There are indications that CDMOs are shifting focus from smaller biotech clients to larger opportunities due to regulatory pressures, which may enhance Lifecore's market position [3]

Core Insights - Lifecore Biomedical has signed an agreement to transfer commercial manufacturing of a leading injectable pharmaceutical product to its facilities, becoming the supplier of choice for this product after meeting regulatory requirements [1][2] - This marks the second agreement with the same multinational organization in recent months, indicating Lifecore's growing reputation for quality and reliability in sterile injectables [1][2] - Additionally, Lifecore has entered into a pre-clinical formulation development agreement with an early-stage biotech company, further expanding its early-stage program pipeline [2] Company Strategy - The commercial site transfer is part of Lifecore's growth strategy to expand its CDMO business and build long-term partnerships with leading global pharmaceutical companies [2] - The new agreement will broaden Lifecore's commercial customer base and increase capacity utilization while allowing entry into new modalities [2] - Lifecore aims to capitalize on strong industry momentum and strengthen its position as a trusted U.S.-based CDMO partner [3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S. The collaboration wil ...

Core Insights - Lifecore Biomedical (NASDAQ: LFCR) is set to release its quarterly earnings on October 3, 2025, with Wall Street anticipating an earnings per share (EPS) of -$0.30 and projected revenue of approximately $26.3 million [1][2] Financial Performance - Despite an expected quarterly loss, Lifecore Biomedical is projected to report a year-over-year increase in earnings driven by revenue growth, making this earnings report crucial for the stock's short-term trajectory [2] - The company has a negative price-to-earnings (P/E) ratio of -6.84, indicating negative earnings, while a price-to-sales ratio of 2.07 reflects investor confidence in its sales potential [3] - The enterprise value to sales ratio is 3.04, providing insights into the company's valuation relative to its sales [3] - A concerning negative enterprise value to operating cash flow ratio of -1899.51 raises doubts about the company's ability to generate positive cash flow from operations [3] - The earnings yield is approximately -14.62%, further emphasizing the company's negative earnings performance [3] Liquidity and Debt Position - Lifecore Biomedical maintains a strong liquidity position with a current ratio of 2.84, indicating its ability to meet short-term liabilities with its assets [4] - The debt-to-equity ratio stands at 2.79, suggesting a significant reliance on debt financing, which will be critical in the upcoming earnings call [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Summary by Sections Investigation Details - The class action complaint was filed on July 29, 2024, covering a class period from October 7, 2020, to March 19, 2024 [1]. - Allegations include that LifeCore made materially false and misleading statements regarding its business operations and financial prospects [2]. - Specific claims include: 1. Deficient internal controls over financial reporting [2]. 2. Issuance of inaccurate financial statements requiring restatement [2]. 3. Ineffective remediation efforts regarding internal control deficiencies [2]. 4. Impaired ability to file periodic reports with the SEC, affecting NASDAQ compliance [2]. 5. Material overstatement of the company's financial position and prospects [2]. 6. Public statements being materially false and misleading throughout the class period [2]. Next Steps for Investors - Long-term stockholders of LifeCore are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. - Contact options include email and telephone, with no cost or obligation for inquiries [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4]. - The firm operates in multiple states, including New York, South Carolina, and California [4].

Core Insights - Lifecore Biomedical (LFCR) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended August 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][12] Earnings Expectations - The consensus EPS estimate for Lifecore Biomedical is a loss of $0.09 per share, which reflects a year-over-year change of +43.4%, while revenues are expected to reach $26.68 million, marking an 8% increase from the previous year [3] - The Most Accurate Estimate for Lifecore Biomedical is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.33%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [12] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 21.43% higher, suggesting a reassessment of initial estimates by covering analysts [4] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, with research indicating that this combination leads to a positive surprise nearly 70% of the time [10] Historical Performance - Lifecore Biomedical has only beaten consensus EPS estimates once in the last four quarters, with the most recent quarter showing a surprise of -11.11% as the company reported a loss of -$0.10 per share against an expected loss of -$0.09 [13][14] Conclusion - Lifecore Biomedical does not currently appear to be a compelling candidate for an earnings beat, and investors are advised to consider other factors when making decisions regarding the stock ahead of its earnings release [17]